Evaluation of the bioMérieux VIDAS HIV Duo Quick and Anti-HCV assays for dried blood spot based serosurveillance.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 06 2022
17 06 2022
Historique:
received:
11
02
2022
accepted:
31
05
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
22
6
2022
Statut:
epublish
Résumé
Serosurveillance is central to monitoring our progress towards HIV and HCV elimination targets proposed for 2030. However, serosurveillance systems are ineffective without reliable serological assays for the detection of HIV and HCV antibodies. Assays should also be compatible with dried blood spot (DBS) samples to facilitate biological sample collection. The VIDAS HIV Duo Quick and Anti-HCV assays are sold as reagents strips and processed by the automated VIDAS benchtop immunoanalyser. While both assays have shown excellent performance in serum and plasma, performance data in DBS samples is lacking. In our study, we evaluate the performance of the VIDAS HIV Duo Quick and Anti-HCV assays in DBS (n = 725) collected during a cross-sectional serosurvey (the Transitions study). The VIDAS HIV Duo quick had a sensitivity and specificity of 94.5% (95% CI 85.1%, 98.5%) and 95.7% (95% CI 93.9%, 97.0%) respectively. Likewise, the VIDAS Anti-HCV had a sensitivity and specificity of 95.6% (95% CI 91.6%, 97.8%) and 95.6% (95% CI 93.5%, 97.0%) respectively. These assays are unlikely to be helpful in low-prevalence settings due to sub-optimal performance, but their performance could likely be improved by optimizing DBS elution protocols which was, unfortunately, not possible during our study.
Identifiants
pubmed: 35715449
doi: 10.1038/s41598-022-14041-z
pii: 10.1038/s41598-022-14041-z
pmc: PMC9205869
doi:
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10171Subventions
Organisme : CIHR
ID : CIHR MOP-13044
Pays : Canada
Informations de copyright
© 2022. The Author(s).
Références
Epidemiology. 2005 Jan;16(1):73-81
pubmed: 15613948
PLoS One. 2019 Oct 17;14(10):e0223573
pubmed: 31622394
Viruses. 2019 Sep 06;11(9):
pubmed: 31489933
Infect Control Hosp Epidemiol. 2021 Jun 24;:1-4
pubmed: 34167599
J Virol Methods. 2004 Dec 15;122(2):185-94
pubmed: 15542143
Diagnostics (Basel). 2021 Mar 15;11(3):
pubmed: 33804260
J Clin Virol. 2016 May;78:20-6
pubmed: 26962723
Ann Lab Med. 2016 Nov;36(6):550-4
pubmed: 27578508
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):91-92
pubmed: 33257831
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Int J Infect Dis. 2021 Oct;111:253-260
pubmed: 34419584
Lancet HIV. 2019 Dec;6(12):e809-e811
pubmed: 31439533
PLoS One. 2021 Dec 7;16(12):e0261003
pubmed: 34874948
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Arch Virol. 2020 Sep;165(9):1947-1958
pubmed: 32617764
Can Commun Dis Rep. 2020 Nov 05;46(11-12):422-426
pubmed: 33776588
J Med Virol. 2011 Sep;83(9):1522-9
pubmed: 21739441
PLoS One. 2017 Oct 20;12(10):e0186722
pubmed: 29053737
J Clin Virol. 2011 Jan;50(1):57-60
pubmed: 20926337
Diagn Microbiol Infect Dis. 2018 Oct;92(2):107-111
pubmed: 29925467
Can Commun Dis Rep. 2020 May 07;46(5):138-148
pubmed: 35283692
J Microbiol Immunol Infect. 2019 Oct;52(5):700-709
pubmed: 29555411